Amboy Street Ventures has invested in Juniper Genomics' $4.6 million seed round to support the development of a groundbreaking embryo screening test aimed at improving IVF outcomes.

Target Information

Amboy Street Ventures is proud to announce its investment in Juniper Genomics, which has successfully closed a $4.6 million seed funding round. Juniper Genomics is pioneering advancements in in vitro fertilization (IVF) through the deployment of the world’s first embryo screening test that utilizes both whole-genome and transcriptome sequencing. This funding round was led by Company Ventures, with notable participation from Amboy Street Ventures, Innospark Ventures, MBX Capital, Dria Ventures, and Blue Collective.

Infertility affects approximately 1 in 6 individuals, and many choose the IVF pathway, which currently boasts a success rate of only 34% per cycle. As a result, patients frequently face multiple emotionally and financially draining cycles. A predominant reason for failed embryo transfers in IVF arises from genetic abnormalities, many of which remain unnoticed by conventional screening techniques.

Industry Overview

In the United States, the assisted reproductive technology (ART) market has been experiencing considerable growth. Increasing infertility rates, coupled with technological advancements in reproductive health, are driving the ado